6′-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding

Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal estrogen therapy promotes unintended side effects, such as hot flashes and increased throm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone Rep
Autors principals: Powell, Katherine M., Brown, Alexa P., Skaggs, Cayla G., Pulliam, Alexis N., Berman, Alycia G., Deosthale, Padmini, Plotkin, Lilian I., Allen, Matthew R., Williams, David R., Wallace, Joseph M.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6992940/
https://ncbi.nlm.nih.gov/pubmed/32016137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2020.100246
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars